• Profile
Close

Is dupilumab effective in adult‐onset atopic dermatitis: Real‐life experience of 16 patients

Journal of Cosmetic Dermatology Feb 03, 2022

Dupilumab appears to have high effectiveness as well as safety in treating adult-onset atopic dermatitis (AD). This research represents the first study to evaluate this patient group specifically.

  • In this retrospective case series, 16 patients (6 female and 10 male; median age 41 years; median age of the disease onset was 37.5 years; median span of the disease was 90 months) with the diagnosis of adult-onset AD, using dupilumab at standard dose for at least 3 months were analyzed.

  • Median duration of the dupilumab therapy was 10.5 months, and mean percent decrease from baseline in eczema area severity index score was 85.8 ± 12.2 at 3 months, 90.7 ± 9.3 at 6 months, and 93.1 ± 5 at 12 months.

  • Compared with the baseline, mean percent reduction in visual analog scale itch score was 82.2 ± 8.6 at 3 months.

  • One patient receiving dupilumab developed acute vestibular neuritis, which resolved with anti-inflammatory therapy.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay